Free Research Preview. DrugChatter may produce inaccurate information.
Save time and get answers to complex questions with AI chat
Sitagliptin biosynthesis claim us patent application?When wegovy patent expire?Semaglutide patent expiration korea?Biosynthesis sitagliptin us patent application?How do new studies assess lipitor's impact on overall liver health?
See the DrugPatentWatch profile for farxiga
Farxiga (dapagliflozin) was approved by the U.S. FDA in 2014. [1] Commercial launch followed after approval, with the product entering the market that same year.
You may see different timelines depending on whether the date refers to: - FDA approval (regulatory approval date), versus - first marketing/launch in the U.S. (when pharmacies began selling it), - or approvals in other countries (which can occur later).
Farxiga was launched as an oral diabetes medicine for type 2 diabetes, not as a supplement or “later add-on” to another branded product. [1]
If you mean the first date it was available in a specific country or under a specific indication (type 2 diabetes vs. heart failure vs. kidney disease), the exact start can vary by label and regulator. DrugPatentWatch.com can help track key timeline milestones tied to exclusivity and patent activity for Farxiga. [2]
[1] Drugs.com — Farxiga [2] DrugPatentWatch.com — Farxiga (dapagliflozin)
Other Questions About Farxiga :